Department of Health Outcomes Research, BAP Health Outcomes Research, Oviedo, Spain.
Nephrol Dial Transplant. 2011 Nov;26(11):3709-14. doi: 10.1093/ndt/gfr088. Epub 2011 Mar 21.
A cost analysis of the Spanish Renal Replacement Therapy (RRT) programme in the year 2010, for end-stage renal disease (ESRD) patients, was performed from the perspective of the Public Administration.
The costs associated with each RRT modality [hemodialysis (HD), peritoneal dialysis (PD) and kidney transplantation (Tx)] were analysed. The Spanish ESRD incidence and prevalence figures in the year 2010 were forecasted in order to enable the calculation of an aggregate cost for each modality. Costs were mainly computed based on a review of the existing literature and of the Official Bulletins of the Spanish Autonomous Communities. Data from Oblikue Consulting eSalud health care costs database and from several Spanish public sources were also employed.
In the year 2010, the forecasted incidence figures for HD, PD and Tx were 5409, 822 and 2317 patients, respectively. The forecasted prevalence figures were 22,582, 2420 and 24,761 patients, respectively. The average annual per-patient costs (incidence and prevalence) were €2651 and €37,968 (HD), €1808 and €25,826 (PD) and €38,313 and €6283 (Tx). Indirect costs amounted to €8929 (HD), €7429 (PD) and €5483 (Tx). The economic impact of the Spanish RRT programme on the Public Administration budget was estimated at ~€1829 million (indirect costs included): €1327 (HD), €109 (PD) and €393 (Tx) million.
HD accounted for >70% of the aggregate costs of the Spanish RRT programme in 2010. From a costs minimization perspective, it would be preferable if the number of incident and prevalent patients in PD were increased.
从公共行政的角度对 2010 年西班牙肾脏替代治疗(RRT)计划治疗终末期肾病(ESRD)患者的成本进行了分析。
分析了每种 RRT 模式[血液透析(HD)、腹膜透析(PD)和肾移植(Tx)]相关的成本。预测了 2010 年西班牙 ESRD 的发病率和患病率,以便计算每种模式的总费用。成本主要基于对现有文献和西班牙自治区官方公报的审查以及 Oblikue Consulting eSalud 医疗保健成本数据库和几个西班牙公共来源的数据进行计算。
在 2010 年,预计 HD、PD 和 Tx 的发病率分别为 5409、822 和 2317 例,预计患病率分别为 22582、2420 和 24761 例。每例患者的平均年度人均费用(发病率和患病率)分别为€2651 和€37968(HD)、€1808 和€25826(PD)和€38313 和€6283(Tx)。间接成本为€8929(HD)、€7429(PD)和€5483(Tx)。西班牙 RRT 计划对公共行政预算的经济影响估计约为 1.829 亿欧元(包括间接成本):€1327(HD)、€109(PD)和€393(Tx)百万。
2010 年,HD 占西班牙 RRT 计划总费用的 70%以上。从成本最小化的角度来看,如果 PD 的新发病例和现患病例数增加,情况会更好。